/
PRTA
$9.97-$0.05 (-0.50%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$524.6M
52M shares
52-week range
$5.96 – $11.80
69% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-41.44
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $955.0K | $814.0K | $853.0K | $200.6M | $53.9M | $91.4M | $135.2M | $9.7M |
| Cost of revenue | $101.2M | $50.8M | $74.9M | $0 | $0 | $0 | $0 | $3.7M |
| Gross profit | −$100.2M | −$50.0M | −$74.0M | $200.6M | $53.9M | $91.4M | $135.2M | $6.0M |
| Gross margin | -10495.1% | -6145.2% | -8678.9% | 100.0% | 100.0% | 100.0% | 100.0% | 61.8% |
| R&D | $101.2M | $50.8M | $75.1M | $82.3M | $135.6M | $220.6M | $222.5M | $134.9M |
| Operating income | −$158.9M | −$85.7M | −$112.7M | $72.0M | −$131.6M | −$191.0M | −$154.6M | −$184.6M |
| EBITDA | −$152.9M | −$84.2M | −$111.2M | $73.0M | −$124.9M | −$159.6M | −$128.0M | −$197.1M |
| Net income | −$155.6M | −$77.7M | −$111.1M | $67.0M | −$116.9M | −$147.0M | −$122.3M | −$244.1M |
| Net margin | -16297.9% | -9542.6% | -13029.8% | 33.4% | -217.0% | -160.9% | -90.5% | -2520.6% |
| EPS (diluted) | -3.93 | -1.95 | -2.78 | 1.38 | -2.47 | -2.76 | -2.27 | -4.53 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $83M | $0.05 | $-0.16–$0.19 | 4 |
| 2027 | $26M | $-1.03 | $-1.19–$-0.76 | 3 |
| 2028 | $135M | $0.17 | $-1.49–$1.09 | 4 |
| 2029 | $201M | $-0.17 | $-0.21–$-0.13 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.46
Price
$9.97
Implied downside
-65%
Peer comparison
Prothena Corporation plc Ordinary Shares
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
www.prothena.com- Employees
- 67
- IPO / List date
- Dec 18, 2012
- HQ
- DUBLIN 2, L2
Held by traders on TradeandTell
No one on the platform currently holds PRTA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in PRTA as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded PRTA yet.
